Connect with us

Health

Asthma may not boost risk for severe COVID-19, study says

Published

on

New research may have people with asthma breathing a little easier: Doctors found the airway disease doesn’t raise the risk of being hospitalized due to COVID-19.

The researchers also noted that people with asthma weren’t more likely than people without it to need a ventilator to help them breathe.

“A lot of people with asthma think they have a predisposition to severe COVID, and they worry a lot about going out. They should take precautions like using their masks, but they may not need to worry so much,” said study author Dr. Fernando Holguin. He’s director of the Asthma Clinical and Research Program at the University of Colorado Anschutz Medical Campus, in Aurora.

Holguin said the proportion of hospitalized COVID-19 patients with asthma was around 6%.

“For most places, that’s an asthma prevalence that is at or lower than the asthma prevalence in the general population. To compare, with influenza [flu], we typically see about a quarter of those in the hospital have asthma,” he said.

When the pandemic first began, the U.S. Centers for Disease Control and Prevention suggested that people with asthma had a higher risk of hospitalization and other severe outcomes. People with asthma do have a significantly higher risk of complications with flu, another viral infection.

In the new study, the researchers reviewed 15 studies on COVID-19 infections to see how many people hospitalized had asthma.

They also looked at more than 400 patients treated for COVID-19 at the University of Colorado Hospital, to see whether the rates of ventilator use were different in people with asthma.

“The message from our study is not to be cavalier about COVID, but individuals with asthma won’t do worse than people without it,” Holguin said.

Other research also points to the same conclusion. A June study in the Journal of Allergy and Clinical Immunology of more than 1,500 people — 220 with asthma — who had COVID-19 found that people with asthma weren’t more likely to be hospitalized. They also didn’t have a higher risk of death.

Holguin said the researchers have a theory as to why COVID-19 infections don’t seem to lead to worse outcomes in people with asthma.

“Allergic asthma is associated with lower numbers of ACE2 receptors. These are the receptors the virus uses to anchor itself to cells,” he said. That means people with allergic asthma may have less area for the virus to attach to. Holguin added that people who use inhaled corticosteroids (an asthma treatment) also have fewer ACE2 receptors.

The new findings were published Aug. 31 in the Annals of the American Thoracic Society.

Dr. Charles Fishman, a pulmonologist with the NewYork-Presbyterian Medical Group Westchester, in New York City, said, “This study’s findings are consistent with what we’ve seen clinically. The original concern was that since people with asthma are disproportionately hospitalized with flu, that they might also have bad outcomes with coronavirus. But that doesn’t seem to be the case with coronavirus.”

Fishman said it’s probably too soon to know why people with asthma are faring better than expected.

“There so much that’s still unknown. It’s important in drawing conclusions that we really rely on good science,” he added.

In the meantime, like Holguin, he advised, “People with asthma should exercise the exact same caution as people without asthma. They don’t need to be increasingly concerned, but should have a healthy respect for what this virus can do. Until a vaccine is available and the population is fully protected, continue to do those things that protect you from the virus [such as wearing a mask, washing your hands frequently and keeping safe distances from others].”

More information

Learn more about asthma from the American College of Allergy, Asthma, and Immunology.

Copyright 2020 HealthDay. All rights reserved.



Source link

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Health

‘Green prescriptions’ could cancel mental health benefits for some

Published

on

So-called “green prescriptions” may end up being counterproductive for people with mental health conditions, researchers say.

Spending time in nature is believed to benefit mental health, so some doctors are beginning to “prescribe” outdoor time for their patients.

That led researchers to investigate whether being in nature helps actually does help people with issues such as anxiety and depression. They collected data from more than 18,000 people in 18 countries.

The takeaway: Time in nature does provide several benefits for people with mental health conditions, but only if they choose on their own to visit green spaces.

While being advised to spend time outdoors can encourage such activity, it can also undermine the potential emotional benefits, according to the authors of the study published this month in the journal Scientific Reports.

The researchers said they were surprised to find that people with depression were spending time in nature as often as folks with no mental health issues, and that people with anxiety were doing so much more often.

While in nature, those with depression and anxiety tended to feel happy and reported low anxiety. But those benefits appeared to be undermined when the visits were done at others’ urging, the investigators found.

The more external pressure people with depression and anxiety felt to visit nature, the less motivated they were to do so and the more anxious they felt.

“These findings are consistent with wider research that suggests that urban natural environments provide spaces for people to relax and recover from stress,” said study leader Michelle Tester-Jones, a postdoctoral research associate at the University of Exeter in the United Kingdom.

But the findings also show that health care practitioners and loved ones should be sensitive about recommending time in nature for people who have mental health issues.

“It could be helpful to encourage them to spend more time in places that people already enjoy visiting, so they feel comfortable and can make the most of the experience,” Tester-Jones said in a university news release.

More information

For more on the benefits of green spaces, go to the National Recreation and Park Association.

Copyright 2020 HealthDay. All rights reserved.



Source link

Continue Reading

Health

Study: Nearly half of ‘essential workers’ in U.S. at risk for severe COVID-19

Published

on

Nov. 9 (UPI) — Nearly half of those classified as “essential workers” in the United States are at increased risk for severe COVID-19, according to an analysis published Monday by JAMA Internal Medicine.

This means that more than 74 million workers and those with whom they live could be at risk for serious illness, based on disease risk guidelines developed by the U.S. Centers for Disease Control and Prevention, the researchers said.

“Many parts of the country face high and rising infection rates, [and] we should not think about work exposure and health risks in isolation, given that workers and persons at increased risk often live in the same households,” study co-author Thomas M. Selden told UPI.

“Insofar as we can reduce the prevalence of COVID-19 in our communities, we can reduce the extent to which policymakers have to choose between the economy and keeping the population safe,” said Selden, an economist with the U.S. Department of Health and Human Services’ Agency for Healthcare Research and Quality.

Since the COVID-19 pandemic spread to the United States in March, states and cities across the country have instituted lockdown measures designed to limit the spread of the disease.

Many of these measures entailed closing schools and non-essential businesses, with only banks, grocery stores, pharmacies and other businesses deemed to provide vital services allowed to stay open.

For this study, Selden and his colleagues analyzed data on the U.S. workforce to examine how many people were in essential jobs, how often they were able to work at home, their risk for severe COVID-19 and the potential health risks for their household members.

Of the more than 157 million workers across the country, 72% are in jobs deemed essential — based on U.S. Department of Homeland Security criteria — and more than three-fourths of all essential workers are unable to work at home, Selden said.

Essential workers include those in the medical and healthcare, telecommunications, information technology systems, defense, food and agriculture, transportation and logistics and energy, water and wastewater industries, as well as those in law enforcement and public works, the DHS criteria stipulates.

The study notes that up to 60% of these workers have underlying health issues, placing them at increased risk for severe COVID-19 if they get infected, as defined by U.S. Centers for Disease Control and Prevention guidelines.

Those with diabetes, heart disease, high blood pressure and chronic respiratory conditions like asthma are considered to be at high risk for serious illness, the CDC says.

Based on these findings, between roughly 57 million and 74 million adults working in on-site essential jobs — and their families — are at increased risk for serious illness, Selden and his colleagues estimated.

“Policymakers face important decisions about how to balance the economic benefits of keeping workers employed and the public health benefits of protecting those with increased risk of severe COVID-19,” Selden said.

“These issues arise in the context of decisions to close segments of the economy and decisions about how to distribute vaccines, which will initially be available only with limited supply, [and] become all the more difficult when the prevalence of infection rises in parts of the country,” he said.



Source link

Continue Reading

Health

Study: Hydroxychloroquine no better than placebo for hospitalized COVID-19 patients

Published

on

Nov. 9 (UPI) — COVID-19 patients treated with hydroxychloroquine showed no signs of significant improvement in “clinical status” compared with those given a placebo, a study published Monday by JAMA found.

Patients given a five-day course of the drug were scored as “category six” based on the World Health Organization’s seven-category COVID Ordinal Outcomes Scale, the same as those given a placebo, the researchers said.

Also, 28 days after they started treatment, 10.4% of those treated with hydroxychloroquine died, just slightly lower than the 10.6% fatality rate in the placebo group.

“The results show that hydroxychloroquine did not help patients recover from COVID-19,” study co-author Dr. Wesley H. Self told UPI.

“In the study, patients treated with hydroxychloroquine and those treated with a placebo had nearly identical outcomes, [so] I do not foresee any role for hydroxychloroquine in acutely ill patients hospitalized with COVID-19,” said Self, an infectious disease specialist at Vanderbilt University Medical Center.

Hydroxychloroquine is an immunosuppressive and anti-parasitic drug that is used to treat malaria.

Early in the COVID-19 pandemic, it was touted by President Donald Trump and others as a potential treatment for the virus, despite the lack of any scientific data supporting its use.

Given its effectiveness helping those sickened with malaria — a mosquito-borne infection — to recover, “there was a strong rationale for why hydroxychloroquine may have been beneficial for patients with COVID-19,” according to Self.

However, in July, the U.S. Food and Drug Administration warned against the drug’s use in the treatment of those infected with the new coronavirus, due to potentially serious heart-related side effects.

For this study, Self and his colleagues treated 433 COVID-19 patients at 34 hospitals across the United States with either the drug or a placebo for a period of five days.

Patients assigned to the hydroxychloroquine group received 400 milligrams of the drug in pill form twice a day for the first two doses and then 200 mg. in pill form twice a day for the next eight doses, for a total of 10 doses over the five days.

All of the patients were then assessed based on the WHO’s COVID Ordinal Outcomes Scale, which categorizes those infected according to disease severity.

Most of the patients in both the hydroxycholorquine group and the placebo group were in “category six,” meaning they were hospitalized and receiving extracorporeal membrane oxygenation or invasive mechanical ventilation to maintain their breathing, the researchers said.

“Our results, especially when combined from other studies conducted in the United Kingdom and Brazil, are good evidence that hydroxychloroquine does not provide benefit for patients hospitalized with COVID-19,” Self said.



Source link

Continue Reading

Trending